Abstract
Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.
Original language | English (US) |
---|---|
Journal | Journal of Biopharmaceutical Statistics |
DOIs | |
State | Accepted/In press - Nov 11 2015 |
Keywords
- Censoring
- cost-effectiveness analysis
- ICER
- median
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Statistics and Probability